Login to Your Account

Hanall grants China rights to Harbour for two novel biologics

By David Ho
Staff Writer

Wednesday, September 13, 2017

HONG KONG – Chinese biotech company Harbour Biomed Therapeutics Ltd. has entered a collaboration and licensing agreement with South Korea's Hanall Biopharma Co. Ltd. for novel biologics.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription